Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
β-Catenin disruption decreases macrophage exosomal α-SNAP and impedes Treg differentiation in acute liver injury
Ruobin Zong, … , Hankun Hu, Changyong Li
Ruobin Zong, … , Hankun Hu, Changyong Li
Published November 19, 2024
Citation Information: JCI Insight. 2025;10(1):e182515. https://doi.org/10.1172/jci.insight.182515.
View: Text | PDF
Research Article Hepatology Immunology

β-Catenin disruption decreases macrophage exosomal α-SNAP and impedes Treg differentiation in acute liver injury

  • Text
  • PDF
Abstract

Hepatic macrophages and regulatory T cells (Tregs) play an important role in the maintenance of liver immune homeostasis, but the mechanism by which hepatic macrophages regulate Tregs in acute liver injury remains largely unknown. Here, we found that the hepatic Treg proportion and β-catenin expression in hepatic macrophages were associated with acetaminophen- and d-galactosamine/LPS–induced acute liver injury. Interestingly, β-catenin was markedly upregulated only in infiltrating macrophages but not in resident Kupffer cells. Myeloid-specific β-catenin–knockout mice showed an increased inflammatory cell infiltration and hepatocyte apoptosis. Moreover, myeloid β-catenin deficiency decreased the hepatic Treg proportion in the injured liver. Mechanistically, in vitro coculture experiments revealed that macrophage β-catenin modulated its exosome composition and influenced Treg differentiation. Using mass spectrometry–based proteomics, we identified that macrophage β-catenin activation increased the level of exosomal alpha soluble NSF attachment protein (α-SNAP), which in turn promoted Treg differentiation. Overall, our findings demonstrated a molecular mechanism that macrophage β-catenin regulated the Treg proportion in the liver by enhancing the expression of exosomal α-SNAP, providing insights into the pathophysiology of acute liver injury.

Authors

Ruobin Zong, Yujie Liu, Mengya Zhang, Buwei Liu, Wei Zhang, Hankun Hu, Changyong Li

×

Figure 2

Myeloid β-catenin deficiency aggravates liver injury and reduces hepatic Treg proportion.

Options: View larger image (or click on image) Download as PowerPoint
Myeloid β-catenin deficiency aggravates liver injury and reduces hepatic...
(A) Representative pictures of H&E staining of liver sections. (B) Hepatocellular function, as assessed by serum ALT/AST levels (IU/L) (n ≥ 5 samples/group). (C) Representative images of TUNEL-staining liver sections and quantification of TUNEL-positive nuclei per high-power field for at least 6 fields per sample. (D–F) Immunohistochemistry staining and quantification of cleaved caspase-3+CD11b+ macrophages and MPO+ neutrophils in the livers. MPO, myeloperoxidase. (G) The proportion of hepatic CD25+Foxp3+ Tregs gated on CD3+CD4+ T cells was analyzed by flow cytometry (n = 9–10 samples/group). Scale bars, 100 μm (A); 20 μm (C); 50 μm (D–F). Data are presented as individual values and represent the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 versus nondiabetic controls by 1-way ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts